These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16422998)

  • 21. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
    McKeage K; Goa KL
    Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children.
    Levine A; Broide E; Stein M; Bujanover Y; Weizman Z; Dinari G; Pacht A; Branski D; Zahavi I
    J Pediatr; 2002 Jan; 140(1):75-80. PubMed ID: 11815767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs.
    Stroup ST; Behrend EN; Kemppainen RJ; Smith-Carr S
    Am J Vet Res; 2006 Jul; 67(7):1173-8. PubMed ID: 16817739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.
    Kolkman JJ; Möllmann HW; Möllmann AC; Penã AS; Greinwald R; Tauschel HD; Hochhaus G
    Drugs Today (Barc); 2004 Jul; 40(7):589-601. PubMed ID: 15510233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ; Feagan BG; Lichtenstein GR
    Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
    Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
    Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis.
    Dilger K; Cascorbi I; Grünhage F; Hohenester S; Sauerbruch T; Beuers U
    Liver Int; 2006 Apr; 26(3):285-90. PubMed ID: 16584389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of budesonide in the treatment of active Crohn's disease is good clinical practice.
    Rutgeerts P
    Inflamm Bowel Dis; 2001 Feb; 7(1):60-61; discussion 62-3. PubMed ID: 11233663
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease.
    Kwapisz L; Jairath V; Khanna R; Feagan B
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):793-801. PubMed ID: 28612627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.
    Levine A; Kori M; Dinari G; Broide E; Shaoul R; Yerushalmi B; On A; Bujanover Y; Pröls M; Greinwald R;
    Inflamm Bowel Dis; 2009 Jul; 15(7):1055-61. PubMed ID: 19229988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Budesonide in Crohn's disease: findings of a compassionate-use program.
    Lyckegaard E; Håkansson K; Bengtsson B
    Hepatogastroenterology; 2007; 54(79):2024-7. PubMed ID: 18251152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.
    Dilger K; Lopez-Lazaro L; Marx C; Bussmann C; Straumann A
    Digestion; 2013; 87(2):110-7. PubMed ID: 23364258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide.
    Weigand K; Wagner-Thiessen E; Stolte M
    Z Gastroenterol; 2004 Oct; 42(10):1179-81. PubMed ID: 15508059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.
    Cohen SA; Aloi M; Arumugam R; Baker R; Bax K; Kierkuś J; Koletzko S; Lionetti P; Persson T; Eklund S
    Curr Med Res Opin; 2017 Jul; 33(7):1261-1268. PubMed ID: 28420280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals.
    Song IH; Finkelman RD; Lan L
    Drugs R D; 2020 Dec; 20(4):359-367. PubMed ID: 33057953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide.
    Fedorak RN; Bistritz L
    Adv Drug Deliv Rev; 2005 Jan; 57(2):303-16. PubMed ID: 15555744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-inflammatory effects of inhaled corticosteroids versus anti-leukotrienes on the lymphocyte P-glycoprotein (PGP) expression in asthmatic children.
    Kopriva F; Dzubak P; Potesil J; Hajduch M
    J Asthma; 2009 May; 46(4):366-70. PubMed ID: 19484671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.